Synthetic Biologics Launches Free Investor Relations Mobile Application
Published on Thursday, 26 April 2012 07:13 Written by TradersHuddle Staff
-- Investors May Download New "SYN IR" iPhone App at Apple's App Store --
ANN ARBOR, Mich., April 26, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today the release of its investor relations mobile iPhone App, called the "SYN IR" App, now available for free at the Apple App Store on the iPhone or iPad or at http://bit.ly/I9xDpW.
The Synthetic Biologics' investor relations mobile iPhone App allows users to navigate the Company's investor relations materials as well as receive a stock quote and other important stock information. Features in the "SYN IR" App include the latest press releases and SEC filings as well as a corporate fact sheet and listing of events.
"The launch of our investor relations iPhone App provides our current and potential shareholders with immediate access to financial and corporate information regarding the Company," stated C. Evan Ballantyne, Chief Financial Officer at Synthetic Biologics. "With investors always on the move and spanning the globe, we recognize the growing importance of mobile technology. This new application allows our shareholders to have instant access to our corporate and stock information. We are excited to be one of the early adopters of mobile technology that is intended to help drive shareholder value and create broader awareness throughout the investment community."
About Synthetic Biologics, Inc.
Synthetic Biologics is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Synthetic Biologics is developing, or has partnered the development of, product candidates for the treatment of pulmonary arterial hypertension (PAH), relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral sclerosis (ALS). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
This release includes forward-looking statements on Synthetic Biologics' current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding driving shareholder value. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics' forward-looking statements include, among others, a failure of the "SYN IR" App to provide its anticipated benefits and other factors described in Synthetic Biologics' report on Form 10-K for the year ended December 31, 2011 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
SOURCE Synthetic Biologics, Inc.
- Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
- Synthetic Biologics Reports First Quarter 2013 Financial Results
- Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
- Synthetic Biologics Reports Year End 2012 Financial Results
- Synthetic Biologics Announces Issuance of U.S. Patent Covering Combination of Estriol and Copaxone® for Multiple Sclerosis
- Synthetic Biologics to Present at the 25th Annual ROTH Conference
- Infectious Disease Specialist, Brad Spellberg, M.D., Joins Synthetic Biologics' Scientific Advisory Board
- Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
Related Partner Headlines
Latest Partner Headlines
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com
Separating the Bargains From the Busts - TheStreet.com
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com
Gap Up and Sit - TheStreet.com
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com
Windows 8 PC Sales Disappointing: Report - TheStreet.com
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Dow JonesCompany ID [INDEXDJX:.DJI] Last trade:15,303.10 Trade time:4:36PM EDT Value change:▲8.60 (0.06%)
S&P 500Company ID [INDEXSP:.INX] Last trade:1,649.60 Trade time:4:35PM EDT Value change:▼0.91 (-0.06%)
NASDAQCompany ID [INDEXNASDAQ:.IXIC] Last trade:3,459.14 Trade time:5:15PM EDT Value change:▼0.28 (-0.01%)
In The Wires
MBAC announces voting results for election of directors and ratification of Advance Notice By-Law
UTC Calls For Redemption Of All Of Its Outstanding 1.200 Percent Notes Due June 1, 2015
Baylake Corp. Approves Common Stock Repurchase Program
FMC Technologies Announces Second Quarter 2013 Earnings Release and Teleconference Schedule
Diageo Thanks Connecticut Legislature and Governor for Continuing to Modernize Beverage Alcohol Laws
Epicore BioNetworks Inc. Quarter Three Fiscal Year 2013
Maidenform Brands, Inc. to Participate in the Citi 2013 Global Consumer Conference to be held at the Hilton New York Hotel in New York City on Wednesday, May 29, 2013
China GengSheng Receives Delinquency Letter from NYSE MKT